Literature DB >> 9208278

Potential uremic toxins modulate energy metabolism of cardiac myocytes in vitro.

D Weisensee1, Y Schnaars, W Schoeppe, J Bereiter-Hahn, I Löw-Friedrich.   

Abstract

In the present study we investigated the direct effects of potential uremic toxins on the energy metabolism of cultured cardiac myocytes. High-energy phosphates were extracted with perchloric acid and determined by high performance liquid chromatography. Energy charge (calculated from the ratio of [ATP], [ADP] and [AMP] was significantly reduced by 20 mM urea and the combination of creatinine (5 mM) plus urea (200 mM). On the other hand, perfusion with culture media containing clinically relevant amounts of urea (20 mM) or creatinine (1 mM) increased the PCr/ATP ratio. This effect was more pronounced after application of an artificial uremic medium (consisting of uremic serum, urea, creatinine and cytokines) or high amounts of creatinine (5 mM) plus urea (200 mM). As contractility of myocytes is reduced due to application of uremic compounds or uremic serum, we attribute changes in contraction frequency or inotropy to dysregulation of calcium availability within the cell. In fact, the cardiodepressive action of uremic serum (2.5%) could be completely reversed by the calcium agonist, Bay K 8644, thus indicating disturbances in myocardial calcium homeostasis in uremia. Altered calcium regulation by uremic toxins might therefore be responsible for the observed changes in myocardial energy metabolism. These results might contribute to the understanding of the pathogenesis of cardiac damage in end-stage renal disease.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9208278

Source DB:  PubMed          Journal:  Exp Nephrol        ISSN: 1018-7782


  4 in total

1.  Anemia and associated clinical outcomes in patients with heart failure due to reduced left ventricular systolic function.

Authors:  Peter A McCullough; Denise Barnard; Robert Clare; Stephen J Ellis; Jerome L Fleg; Gregg C Fonarow; Barry A Franklin; Ryan D Kilpatrick; Dalane W Kitzman; Christopher M O'Connor; Ileana L Piña; Udho Thadani; Vinay Thohan; David J Whellan
Journal:  Clin Cardiol       Date:  2013-08-08       Impact factor: 2.882

2.  Impact of reduced kidney function on cardiopulmonary fitness in patients with systolic heart failure.

Authors:  Peter A McCullough; Barry A Franklin; Eric Leifer; Gregg C Fonarow
Journal:  Am J Nephrol       Date:  2010-07-22       Impact factor: 3.754

3.  Cardiotoxicity of cyclophosphamide's metabolites: an in vitro metabolomics approach in AC16 human cardiomyocytes.

Authors:  Flávio Dionísio; Ana Margarida Araújo; Margarida Duarte-Araújo; Maria de Lourdes Bastos; Paula Guedes de Pinho; Félix Carvalho; Vera Marisa Costa
Journal:  Arch Toxicol       Date:  2022-01-28       Impact factor: 5.153

Review 4.  Gut Microbiota and Cardiovascular Uremic Toxicities.

Authors:  Manuel T Velasquez; Patricia Centron; Ian Barrows; Rama Dwivedi; Dominic S Raj
Journal:  Toxins (Basel)       Date:  2018-07-11       Impact factor: 4.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.